Fidanacogene elaparvovec
Generic name: fidanacogene elaparvovec [ FYE-da-NAK-oh-jeen-EL-a-PAR-voe-vek ]
Brand names: Beqvez (115-135 kg), Beqvez (75-95 kg), Beqvez (95-115 kg), Beqvez (upto 75 kg)
Dosage form: intravenous suspension (dzkt 10 trillion vg/mL)
Drug class: Miscellaneous coagulation modifiers
What is fidanacogene elaparvovec?
Fidanacogene elaparvovec is used to treat a bleeding disorder called hemophilia B in adult men who are receiving preventive treatment for the condition, have recurrent episodes of serious bleeding or have current or previous life-threatening bleeding events.
Your doctor will make sure you have the correct gene type to be treated with fidanacogene elaparvovec.
Fidanacogene elaparvovec may also be used for purposes not listed in this medication guide.
Fidanacogene elaparvovec side effects
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Some side effects may occur during or right after the injection. Tell your medical caregiver if you feel dizzy, nauseated, light-headed, itchy, sweaty, or have a headache, chest tightness, back pain, trouble breathing, unusual bleeding, or swelling in your face.
Common side effects of fidanacogene elaparvovec may include:
-
abnormal liver tests.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Related/similar drugs
Hemgenix
Hemgenix (etranacogene dezaparvovec-drlb) is a gene therapy indicated for the treatment of adults ...
BeneFix
BeneFix (coagulation factor IX) is a once-weekly, injectable, treatment for hemophilia B that may ...
Benlysta
Benlysta infusion is used to treat active systemic lupus erythematosus (SLE) and active lupus ...
Hympavzi
Hympavzi (marstacimab-hncq) may be used to prevent or reduce the frequency of bleeding episodes ...
Alprolix
Alprolix is used in hemophilia B to help control and prevent bleeding, it is a coagulation Factor ...
Idelvion
Idelvion (coagulation factor ix recombinant, albumin fusion protein) is a long-acting, injectable ...
Profilnine
Profilnine is used for factor ix deficiency, factor vii deficiency, hemophilia a with inhibitors ...
Beqvez
Beqvez (fidanacogene elaparvovec-dzkt) is an one-time, injectable, viral vector-based gene therapy ...
NovoSeven RT
NovoSeven RT (coagulation Factor VIIa, recombinant) is an injectable, coagulation factor VIIa that ...
Warnings
fidanacogene elaparvovec may not work for every person who receives it. Talk to your doctor if you have any questions.
Before taking this medicine
Tell your doctor if you have or have ever had:
-
unusual bleeding, any bleeding that will not stop;
-
allergic to factor IX complex replacement products;
-
hepatitis B or C;
-
enlarged spleen;
-
HIV (human immunodeficiency virus);
-
if you are scheduled to receive a vaccine;
-
if you drink large amounts of alcohol; or
-
cirrhosis or other liver disease.
Make sure you are current on all vaccines before you start treatment with fidanacogene elaparvovec. Your doctor may need to adjust your vaccination schedule.
Using fidanacogene elaparvovec may carry the risk of developing liver cancer. Ask your doctor about your individual risk.
This medicine is not intended for use by women.
Men using fidanacogene elaparvovec should use condoms or practice abstinence, and avoid donating sperm for up to 6 months after receiving treatment.
Your name should be listed on a registry to track the effects of this medicine on you.
How is fidanacogene elaparvovec given?
Your doctor will perform tests to make sure fidanacogene elaparvovec is the right treatment for you.
Fidanacogene elaparvovec is given in one dose and is injected into a vein by a healthcare provider.
You will be watched during and for at least 3 hours after the infusion to make sure you do not have a reaction.
Doses are based on height and weight. Your dose may change if you gain or lose weight or if you are still growing.
You will need your liver function checked once or twice a week for at least 4 months after treatment.
You may be prescribed other medications to help treat abnormal liver function tests. Keep taking these medicines for as long as your doctor has prescribed.
Tell your doctor ahead of time if you need surgery or a medical procedure or if any bleeding occurs after receiving fidanacogene elaparvovec.
Call your doctor if your symptoms do not improve, or if they get worse.
You may need other medical tests for a longer period of time after treatment if you have certain conditions or if you have certain side effects.
You or your caregiver should practice proper hand hygiene when coming into direct contact with your urine, feces, saliva, mucus, and semen for 6 months after receiving fidanacogene elaparvovec. Place any materials that may have your body waste or fluids in a sealed plastic bag and dispose in regular trash.
Fidanacogene elaparvovec dosing information
Usual Adult Dose for Hemophilia B:
5 x 10(11) vector genomes per kg (vg/kg) of body weight IV once as a single dose
Calculation of patient's dose weight:
-BMI 30 kg/m2 or less: Dose Weight = Actual body weight
-BMI greater than 30 kg/m2: Dose Weight (kg) = 30 kg/m2 x [Height(m)]2
Calculation of patient's dose volume in mL: Dose weight in kg divided by 20 = dose in mL
-The division factor 20 represents the amount of vector genomes per mL of the suspension (1 x 10[13] vg/mL) divided by the per kg dose (5 x 10[11] vg/kg).
Comments:
-For one-time single dose IV infusion only
-Dosing is based on BMI in kg/m2.
-Diluted suspension should be administered as a peripheral IV infusion over approximately 60 minutes (3 mL/min).
-Safety and efficacy have not been established in patients 65 years or older.
-For examples of dose calculation, refer to the manufacturer product information.
Use: For the treatment of adults with moderate to severe hemophilia B (congenital factor IX deficiency) who use factor IX prophylaxis therapy, OR have current or historical life-threatening hemorrhage, OR have repeated serious bleeding episodes, AND do not have neutralizing antibodies to adeno-associated virus serotype Rh74var (AAVRh74var) capsid as detected by a US FDA-approved test
What happens if I miss a dose?
Fidanacogene elaparvovec is used as a single dose and does not have a dosing schedule.
What happens if I overdose?
In a medical setting an overdose would be treated quickly.
What should I avoid after receiving fidanacogene elaparvovec?
Avoid drinking large amounts of alcohol for the first year after treatment. Drinking alcohol may increase your risk of liver damage.
What other drugs will affect fidanacogene elaparvovec?
Tell your doctor if you use certain medicines for infections, birth control, high cholesterol, seizures, pain, or arthritis (including Advil).
Other drugs may affect fidanacogene elaparvovec, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.
More about fidanacogene elaparvovec
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous coagulation modifiers
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Copyright 1996-2025 Cerner Multum, Inc. Version: 1.01.